Phoenix Financial Ltd. increased its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 153.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,014,617 shares of the company's stock after buying an additional 1,219,958 shares during the quarter. Phoenix Financial Ltd. owned 0.84% of Cellebrite DI worth $32,232,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in CLBT. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Cellebrite DI in the first quarter worth approximately $269,000. Manning & Napier Advisors LLC purchased a new position in shares of Cellebrite DI in the first quarter worth approximately $1,979,000. Robeco Institutional Asset Management B.V. purchased a new position in shares of Cellebrite DI in the first quarter worth approximately $3,838,000. Teacher Retirement System of Texas boosted its holdings in shares of Cellebrite DI by 121.3% in the first quarter. Teacher Retirement System of Texas now owns 44,407 shares of the company's stock worth $863,000 after buying an additional 24,337 shares during the last quarter. Finally, Meritage Portfolio Management boosted its holdings in shares of Cellebrite DI by 102.5% in the first quarter. Meritage Portfolio Management now owns 60,559 shares of the company's stock worth $1,177,000 after buying an additional 30,658 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company's stock.
Cellebrite DI Stock Performance
CLBT stock opened at $18.05 on Tuesday. Cellebrite DI Ltd. has a one year low of $13.10 and a one year high of $26.30. The company's fifty day moving average price is $17.32 and its 200-day moving average price is $16.91. The company has a market capitalization of $4.32 billion, a PE ratio of -23.75, a price-to-earnings-growth ratio of 3.30 and a beta of 1.29.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The firm had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. During the same quarter in the previous year, the firm earned $0.10 earnings per share. The company's quarterly revenue was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
CLBT has been the topic of several analyst reports. Lake Street Capital lowered their price target on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a report on Friday, August 15th. JPMorgan Chase & Co. lifted their price target on shares of Cellebrite DI from $20.00 to $23.00 and gave the company an "overweight" rating in a report on Wednesday, September 24th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Cellebrite DI in a report on Wednesday, October 8th. Wall Street Zen raised shares of Cellebrite DI from a "hold" rating to a "buy" rating in a report on Friday, September 26th. Finally, Needham & Company LLC lowered their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $21.75.
Check Out Our Latest Stock Analysis on CLBT
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Stories
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
